coblopasvir (KW 136) / Beijing Kawin - LARVOL DELTA

THE CLINICAL EPIDEMIOLOGY AND TREATMENT OF ACUTE HEPATITIS C CAUSED BY UNSAFE CLINICAL PRACTICES (AASLD 2025) - "Among the 47 patients who received DAA therapy, the regimens used were as follows: sofosbuvir/velpatasvir in 24 patients (33.3%), emitasvir/sofosbuvir in 20 patients (27.8%), ledipasvir/sofosbuvir in 2 patients (2.8%), and coblopasvir/sofosbuvir in 1 patient (1.4%). This outbreak highlights the risks of unsafe clinical practices and the importance of early detection and treatment of AHC. DAA therapy was highly effective, with all treated patients achieving SVR12. Strengthened infection control and timely intervention are crucial to preventing similar events."

Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) retreatment achieves sustained virological response in direct-acting antiviral experienced patients with hepatitis C virus: a (APASL 2025) - "All participants were DAAs treatment experienced, including Sofosbuvir/Velpatesvir (SOF/VEL, 43.8%), Elbasvir/Grazoprevir (EBR/GZR, 25.0%), Coblopasvir/Sofosbuvir (CLP/SOF, 18.8%) and ledipasvir/Sofosbuvir (LDV/SOF, 12.3%). This real-world study confirms high efficacy and safety of SOF/VEL/VOX for the treatment of DAA-experienced chronic hepatitis C patients, even those with GT3b or cirrhosis in China. Treatment was well tolerated well, even in those received SOF/VEL/VOX plus ribavirin. Table and Figure:Figure 1.Table 1 Patient demographics and baseline characteristics"

Clinical • Fibrosis • Hematological Disorders • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Oncology • Solid Tumor

Analysis of the efficacy and safety of coblopasvir and sofosbuvir treatment for Chinese patients with hepatitis C virus genotype 3 infection (APASL 2025) - "The combination of coblopasvir and sofosbuvir achieved a high SVR12 rate and favorable biochemical response in Chinese patients with genotype 3 chronic hepatitis C. These findings suggest that the coblopasvir plus sofosbuvir regimen is both effective and well-tolerated in this population. Table and Figure:Figure 1.Figure 1 Changes in biochemical markers, liver stiffness measurements, and glomerular filtration rate before and after treatment with coblopasvir plus sofosbuvir in patients with chronic HCV genotype 3 infection in China"

Clinical • Fibrosis • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Efficacy and Safety of Coblopasvir and Sofosbuvir in Patients with Hepatitis C in Northwest China (APASL 2025) - "The combination of Colopaivir and sofobuvir in patients with various genotypes of hepatitis C in Northwest China demonstrated superior viral clearance and SVR12 rates, irrespective of the presence or absence of cirrhosis. The administration of this treatment also facilitates improvements in liver biochemical markers and exhibits no significant adverse effects on renal function, thereby demonstrating a favorable safety profile Table and Figure:Figure 1.HCV genotype distribution Figure 2.Alterations in hematological parameters and hepatic biochemical marker"

Clinical • Fibrosis • Hematological Disorders • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Liver Cirrhosis

Efficacy and safety of coblopasvir plus sofosbuvir treatment for Chinese patients with chronic HCV infection: a large-scale, multicenter retrospective study (APASL 2025) - "The 12-week regimen of coblopasvir in combination with sofosbuvir displayed high efficacy and a favorable safety profile in Chinese patients with chronic HCV infection, including those with genotype 3 or 6, advanced age, compensated or decompensated cirrhosis and moderate to severe renal injury. Table and Figure:Figure 1.Table 1 Baseline characteristics and virological response after treatment of coblopasvir with sofosbuvir among multi-center Chinese patients with chronic HCV infection"

Retrospective data • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Oncology • Renal Disease • Solid Tumor

Coblopasvir and sofosbuvir treatment for Chinese patients with chronic HCV infection is safe and efficacious: a real-world study (APASL 2025) - "The 12-week regimen of coblopasvir plus sofosbuvir demonstrated high efficacy and safety in Chinese patients with chronic HCV infection, including those with advanced age, compensated or decompensated cirrhosis, and mild to moderate renal injury. Table and Figure:Figure 1.Table1 Baseline characteristics and virological response after DAAs treatment of coblopasvir and sofosbuvir among Chinese patients with chronic HCV infection Figure 2.Figure 1 Changes in ALT, AST, LSM and eGFR before and after DAAs treatment with coblopasvir and sofosbuvir among Chinese patients with chronic HCV infection"

Clinical • Real-world • Real-world evidence • Diabetes • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Metabolic Disorders • Oncology • Renal Disease • Solid Tumor

EFFECTIVENESS AND SAFETY OF SOFOBUVIR/VELPATASVIR/VOXILAPREVIR AS A RESCUE THERAPY FOR CHRONIC HEPATITIS C PATIENTS WITH FAILED PREVIOUS DIRECT-ACTING ANTIVIRALS TREATMENT IN SOUTHWEST CHINA (AASLD 2023) - "The previous failed DAA regimen include sofosbuvir/velpatasvir (SOF/VEL, n=9, 75.0%), sofosbuvir plus coblopasvir (SOF plus CLP, n=3, 25.0%)...All patients with GT 3b received SOF/VEL/VOX plus ribavirin (RBV) combination therapy, and the other 2 patients received SOF/VEL/VOX monotherapy... SOF/VEL/VOX was effective and well-tolerated for difficult-to-treat DAA experienced CHC patients in China, including those with GT3b and cirrhosis."

Clinical • Fibrosis • Gastroenterology • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Hepatitis C Virus: Insights Into Its History, Treatment, Challenges, and Future Directions. (PubMed, Cureus) - "Additionally, ongoing clinical trials have shown promising results for other drugs such as CDI31244/sofosbuvir/velpatasvir, sofosbuvir/coblopasvir, and daclatasvir/asunaprevir. Furthermore, the ability of HCV to mutate limits the potential for vaccine development. Therefore, it is crucial to focus on developing more cost-effective strategies to control the spread of HCV and create novel, highly effective, and affordable DAAs."

Journal • Review • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Sofosbuvir/Velpatasvir/Voxilaprevir for Direct-acting Antiviral Treatment Experienced Patients with Hepatitis C Virus Infection: Case Series Report from A Single Centre in Southwest China (APASL 2023) - "1 GT3b patient with compensated cirrhosis(CC) used to receive Coblopasvir+SOF+RBV. SOF/VEL/VOX was effective and well tolerated for difficult-to-treat DAA experienced CHC patients, including those with GT3b and cirrhosis. 840"

Clinical • Fibrosis • Gastroenterology • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study. (clinicaltrials.gov) - P=N/A | N=450 | Not yet recruiting | Sponsor: Beijing Tsinghua Chang Gung Hospital

New trial • Real-world evidence • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial. (PubMed, Liver Int) - "The universal, pangenotypic combo of coblopasvir plus sofosbuvir is an efficacious and safe treatment for Chinese patients monoinfected with HCV of genotype 1, 2, 3 and 6, including those with compensated cirrhosis."

Clinical • Journal • P3 data • Fatigue • Fibrosis • Hematological Disorders • Hepatitis C Virus • Hepatology • Immunology • Infectious Disease • Neutropenia

PAN-GENOTYPIC REGIMEN OF COBLOPASVIR PLUS SOFOSBUVIR FOR TREATMENT OF CHRONIC HEPATITIS C IN CHINA: A SINGLE-ARM, OPEN-LABEL, PHASE 3 TRIAL (AASLD 2019) - "The universal, pan-genotypic combination regimen of coblopasvir and sofosbuvir resulted in a high SVR and favorable safety profile in Chinese patients infected with HCV of GT-1, 2, 3 and 6, including those with advanced fibrosis or compensated cirrhosis."

Clinical • P3 data

Safety and efficacy of coblopasvir and sofosbuvir in patients with genotype 1, 2, 3, and 6 HCV infections without or with compensated cirrhosis. (PubMed, J Viral Hepat) - "Most adverse events (AEs) did not require treatment. Coblopasvir plus sofosbuvir taken once daily for 12 weeks provided high rates of sustained virologic response (SVR) and had a good safety profile among patients with HCV genotype 1, 2, 3, or 6 infections, including those with compensated cirrhosis."

Clinical • Journal